Q2-osavuosiraportti
21 päivää sitten‧37 min
Tarjoustasot
Oslo Børs
Määrä
Osto
50 000
Myynti
Määrä
4 000
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| - | - | - | - |
Ylin
-VWAP
Alin
-Vaihto ()
VWAP
Ylin
-Alin
-Vaihto ()
Välittäjätilasto
Dataa ei löytynyt
Yhtiötapahtumat
| Seuraava tapahtuma | |
|---|---|
Sijoittajakalenteri ei ole saatavilla | |
| Menneet tapahtumat | ||
|---|---|---|
| 2025 Q2-osavuosiraportti | 28.8. | |
| 2024 Yhtiökokous | 5.6. | |
| 2024 Q4-osavuosiraportti | 10.4. | |
| 2024 Q2-osavuosiraportti | 29.8.2024 | |
| Merkintäoikeusanti | 20.6.2024 |
Datan lähde: Millistream, Quartr
Asiakkaat katsoivat myös
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
23 t sitten·I think the next few months can be very exciting and have taken a position again 🙂 On September 28th, the agreement expires, in which Atlas could acquire 30% of the company. After that, one can hope that a cooperation agreement with a partner/secret partner can emerge :) They have said several, in 2025, and 2026 💪🏽 Entry around 60-62øre seems quite stable and good 😃
16 t sitten·This could take years and days, but I'm still holding on to my 25,000 shares! Whether I lose 25,000 or 10,000 doesn't matter. I had faith in the company. But if things go wrong, the state covers almost 40% of the loss.
1 päivä sitten · Muokattu·MedWatch Latest Search Menu Drugs & Biotech Medtech & diagnostics Digital Health Regulation & Politics Discussion Career Clinical success could be historic – these biotech companies are nearing the finish line MedWatch has mapped the position of Norwegian biotech companies in the race to the market. Who could be the first company to give Norway a new drug – over ten years after Algeta's Xofigo success? BIOTECH LEADERS: These are leaders of Norwegian clinical-stage biotech: Michael Engsig (left), Nykode, Christian Kersten, Akigai, Øystein Rekdal, Lytix, Rizwan Hussain, Agiana, Øystein Soug, Oncoinvent, Thomas Bjarnsholt, Softox, Lars Prestegården, Cytovation, Per Walday, Exact, Arctic Bioscience, Christer Valderhaug, Erik Wiklund, Circio, Mark Gaffney, Calluna Pharma, Namir Hassan, Zelluna, Christian Lütken, Pharma Holding, Zeno Albisser, Hemispherian, Emanuele Ostuni, Artbio, Jethro Holter, Adjutec. | Photo: Marius Åmbakk Bjørkedal/Vidar Sandnes/Sebastian Brauer Hagel/Softox Solutions/Calluna Pharma/Hemispherian/Artbio/Arcticzymes BIOTICS LEADERS: These are the leaders of Norwegian biotech in clinical phase: Michael Engsig (left), Nykode, Christian Kersten, Akigai, Øystein Rekdal, Lytix, Rizwan Hussain, Agiana, Øystein Soug, Oncoinvent, Thomas Bjarnsholt, Softox, Lars Prestegården, Cytovation, Per Walday, Exact, Arctic Bioscience, Christer Valderhaug, Erik Wiklund, Circio, Mark Gaffney, Calluna Pharma, Namir Hassan, Zelluna, Christian Lütken, Pharma Holding, Zeno Albisser, Hemispherian, Emanuele Ostuni, Artbio, Jethro Holter, Adjutec. | Photo: Marius Åmbakk Bjørkedal/Vidar Sandnes/Sebastian Brauer Hagel/Softox Solutions/Calluna Pharma/Hemispherian/Artbio/Arcticzymes Sebastian Brauer Hagel Sebastian Brauer Hagel Already a subscriber? Log in here Get access to everything from MedWatch Personal subscription Annual payment Save 20% Full access for one person 6,880.00 NOK / year* Excl. VAT Price incl. VAT displayed at checkout Personal subscription Quarterly payment Full access for one person 2,150.00 NOK / quarter** Excl. VAT Price incl. VAT displayed at checkout Corporate subscription Multiple users Full access for multiple users Attractive price per user Try MedWatch for 14 days - and get access to all content. Get a non-binding trial subscription here. * Continues as an ongoing subscription and is billed annually. After 5 months of subscription, can be terminated with 1 month's notice until the end of a month. Minimum price is up to 4,013.33 NOK incl. VAT. equivalent to 7 months of subscription. Right of withdrawal according to the Consumer Contracts Act. Read more here. ** Continues as an ongoing subscription for 3 months at a time. Minimum price 2,150.00 NOK incl. VAT.. Can be terminated with 1 month's notice until the end of a 3-month period. Right of withdrawal according to the Consumer Purchases Act. Read more here. Share article Related articles MUST CHOOSE A PATH: A discovery made by oncologist Christian Kersten and colleagues over 15 years ago has grown into the drug candidate AKI-007. Now the company is faced with a choice: out-license internationally or build the company in Norway. | Photo: Marius Åmbakk Bjørkedal / Medwatch Behind what could be Norway's next drug on the market - must make crucial choices READY FOR CLINICAL STUDY: Margaret Yu, Medical Director of Artbio, is, together with the rest of the company, ready to enter the company's first phase 1 study. Artbio ready for phase 1 studies in the USA PRE-CLINICAL: Arctic Bioscience is approaching the pre-clinical phase for a new drug candidate, for the treatment of normal brain development in extremely premature children. | Photo: Marius Åmbakk Bjørkedal Refuses to give up after study failure Sign up for our newsletter Be ahead of the curve. Get information about the latest from the industry with our newsletter. Email address PITCHE WINNERS: From left: Nicolaj Højer Nielsen (Investor), Benedikte Stavik (winner), Mohammed Amarzguioui (Inven2), Morten Egeberg (SPARK). Joachim Paasche (Aleap/Veksthuset) also sat on the jury. Not pictured: Giacomo Roman. | Photo: Anne-Marie Korseberg Stokke. Research duo wins pitch competition with new hemorrhoid treatment These will forge biotech Norway with new accelerator program OUS researcher wins Nordic innovation competition CLEANING IN THE MANAGEMENT HIERARCHY: Maziar Mike Doustdar announced thousands of layoffs last week both in Denmark and internationally as part of the plan to turn around the crisis-stricken company. | Photo: Novo Nordisk Novo Nordisk clears job titles IMPROVEMENTS: Sanofi is demanding improvements in the British business environment if they are to continue investing in the country. However, the office pictured here is in France, at Vitry sur Seine. | Photo: AP Photo/Michel Euler/NTB Sanofi also freezes British investments DRUG BREXIT: MSD, Astra Zeneca and Eli Lilly are among the companies that are now reassessing investments in the UK. | Photo: Colourbox Pharmaceutical giants turn their backs on the UK – believe NHS policy scares away investments AMBITION: Ulrik Therkildsen and Human Bytes have an ambition to expand the agreement with South-Eastern Health to cover the entire country- 1 päivä sitten · Muokattu·Circio has also not come up with a new date for the next quarterly report?????? Now it's win or lose for the company so we'll see which way it goes 😇
- 1 päivä sitten · Muokattu·Now Erik needs a real kick in the ass so he can give something back to his investors who have been long in this and believed in..........???? Time to cough up something concrete 🙉
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Uutiset ja analyysit
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Q2-osavuosiraportti
21 päivää sitten‧37 min
Uutiset ja analyysit
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
- 23 t sitten·I think the next few months can be very exciting and have taken a position again 🙂 On September 28th, the agreement expires, in which Atlas could acquire 30% of the company. After that, one can hope that a cooperation agreement with a partner/secret partner can emerge :) They have said several, in 2025, and 2026 💪🏽 Entry around 60-62øre seems quite stable and good 😃16 t sitten·This could take years and days, but I'm still holding on to my 25,000 shares! Whether I lose 25,000 or 10,000 doesn't matter. I had faith in the company. But if things go wrong, the state covers almost 40% of the loss.
- 1 päivä sitten · Muokattu·MedWatch Latest Search Menu Drugs & Biotech Medtech & diagnostics Digital Health Regulation & Politics Discussion Career Clinical success could be historic – these biotech companies are nearing the finish line MedWatch has mapped the position of Norwegian biotech companies in the race to the market. Who could be the first company to give Norway a new drug – over ten years after Algeta's Xofigo success? BIOTECH LEADERS: These are leaders of Norwegian clinical-stage biotech: Michael Engsig (left), Nykode, Christian Kersten, Akigai, Øystein Rekdal, Lytix, Rizwan Hussain, Agiana, Øystein Soug, Oncoinvent, Thomas Bjarnsholt, Softox, Lars Prestegården, Cytovation, Per Walday, Exact, Arctic Bioscience, Christer Valderhaug, Erik Wiklund, Circio, Mark Gaffney, Calluna Pharma, Namir Hassan, Zelluna, Christian Lütken, Pharma Holding, Zeno Albisser, Hemispherian, Emanuele Ostuni, Artbio, Jethro Holter, Adjutec. | Photo: Marius Åmbakk Bjørkedal/Vidar Sandnes/Sebastian Brauer Hagel/Softox Solutions/Calluna Pharma/Hemispherian/Artbio/Arcticzymes BIOTICS LEADERS: These are the leaders of Norwegian biotech in clinical phase: Michael Engsig (left), Nykode, Christian Kersten, Akigai, Øystein Rekdal, Lytix, Rizwan Hussain, Agiana, Øystein Soug, Oncoinvent, Thomas Bjarnsholt, Softox, Lars Prestegården, Cytovation, Per Walday, Exact, Arctic Bioscience, Christer Valderhaug, Erik Wiklund, Circio, Mark Gaffney, Calluna Pharma, Namir Hassan, Zelluna, Christian Lütken, Pharma Holding, Zeno Albisser, Hemispherian, Emanuele Ostuni, Artbio, Jethro Holter, Adjutec. | Photo: Marius Åmbakk Bjørkedal/Vidar Sandnes/Sebastian Brauer Hagel/Softox Solutions/Calluna Pharma/Hemispherian/Artbio/Arcticzymes Sebastian Brauer Hagel Sebastian Brauer Hagel Already a subscriber? Log in here Get access to everything from MedWatch Personal subscription Annual payment Save 20% Full access for one person 6,880.00 NOK / year* Excl. VAT Price incl. VAT displayed at checkout Personal subscription Quarterly payment Full access for one person 2,150.00 NOK / quarter** Excl. VAT Price incl. VAT displayed at checkout Corporate subscription Multiple users Full access for multiple users Attractive price per user Try MedWatch for 14 days - and get access to all content. Get a non-binding trial subscription here. * Continues as an ongoing subscription and is billed annually. After 5 months of subscription, can be terminated with 1 month's notice until the end of a month. Minimum price is up to 4,013.33 NOK incl. VAT. equivalent to 7 months of subscription. Right of withdrawal according to the Consumer Contracts Act. Read more here. ** Continues as an ongoing subscription for 3 months at a time. Minimum price 2,150.00 NOK incl. VAT.. Can be terminated with 1 month's notice until the end of a 3-month period. Right of withdrawal according to the Consumer Purchases Act. Read more here. Share article Related articles MUST CHOOSE A PATH: A discovery made by oncologist Christian Kersten and colleagues over 15 years ago has grown into the drug candidate AKI-007. Now the company is faced with a choice: out-license internationally or build the company in Norway. | Photo: Marius Åmbakk Bjørkedal / Medwatch Behind what could be Norway's next drug on the market - must make crucial choices READY FOR CLINICAL STUDY: Margaret Yu, Medical Director of Artbio, is, together with the rest of the company, ready to enter the company's first phase 1 study. Artbio ready for phase 1 studies in the USA PRE-CLINICAL: Arctic Bioscience is approaching the pre-clinical phase for a new drug candidate, for the treatment of normal brain development in extremely premature children. | Photo: Marius Åmbakk Bjørkedal Refuses to give up after study failure Sign up for our newsletter Be ahead of the curve. Get information about the latest from the industry with our newsletter. Email address PITCHE WINNERS: From left: Nicolaj Højer Nielsen (Investor), Benedikte Stavik (winner), Mohammed Amarzguioui (Inven2), Morten Egeberg (SPARK). Joachim Paasche (Aleap/Veksthuset) also sat on the jury. Not pictured: Giacomo Roman. | Photo: Anne-Marie Korseberg Stokke. Research duo wins pitch competition with new hemorrhoid treatment These will forge biotech Norway with new accelerator program OUS researcher wins Nordic innovation competition CLEANING IN THE MANAGEMENT HIERARCHY: Maziar Mike Doustdar announced thousands of layoffs last week both in Denmark and internationally as part of the plan to turn around the crisis-stricken company. | Photo: Novo Nordisk Novo Nordisk clears job titles IMPROVEMENTS: Sanofi is demanding improvements in the British business environment if they are to continue investing in the country. However, the office pictured here is in France, at Vitry sur Seine. | Photo: AP Photo/Michel Euler/NTB Sanofi also freezes British investments DRUG BREXIT: MSD, Astra Zeneca and Eli Lilly are among the companies that are now reassessing investments in the UK. | Photo: Colourbox Pharmaceutical giants turn their backs on the UK – believe NHS policy scares away investments AMBITION: Ulrik Therkildsen and Human Bytes have an ambition to expand the agreement with South-Eastern Health to cover the entire country
- 1 päivä sitten · Muokattu·Circio has also not come up with a new date for the next quarterly report?????? Now it's win or lose for the company so we'll see which way it goes 😇
- 1 päivä sitten · Muokattu·Now Erik needs a real kick in the ass so he can give something back to his investors who have been long in this and believed in..........???? Time to cough up something concrete 🙉
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Oslo Børs
Määrä
Osto
50 000
Myynti
Määrä
4 000
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| - | - | - | - |
Ylin
-VWAP
Alin
-Vaihto ()
VWAP
Ylin
-Alin
-Vaihto ()
Välittäjätilasto
Dataa ei löytynyt
Asiakkaat katsoivat myös
Yhtiötapahtumat
| Seuraava tapahtuma | |
|---|---|
Sijoittajakalenteri ei ole saatavilla | |
| Menneet tapahtumat | ||
|---|---|---|
| 2025 Q2-osavuosiraportti | 28.8. | |
| 2024 Yhtiökokous | 5.6. | |
| 2024 Q4-osavuosiraportti | 10.4. | |
| 2024 Q2-osavuosiraportti | 29.8.2024 | |
| Merkintäoikeusanti | 20.6.2024 |
Datan lähde: Millistream, Quartr
Q2-osavuosiraportti
21 päivää sitten‧37 min
Uutiset ja analyysit
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Yhtiötapahtumat
| Seuraava tapahtuma | |
|---|---|
Sijoittajakalenteri ei ole saatavilla | |
| Menneet tapahtumat | ||
|---|---|---|
| 2025 Q2-osavuosiraportti | 28.8. | |
| 2024 Yhtiökokous | 5.6. | |
| 2024 Q4-osavuosiraportti | 10.4. | |
| 2024 Q2-osavuosiraportti | 29.8.2024 | |
| Merkintäoikeusanti | 20.6.2024 |
Datan lähde: Millistream, Quartr
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
- 23 t sitten·I think the next few months can be very exciting and have taken a position again 🙂 On September 28th, the agreement expires, in which Atlas could acquire 30% of the company. After that, one can hope that a cooperation agreement with a partner/secret partner can emerge :) They have said several, in 2025, and 2026 💪🏽 Entry around 60-62øre seems quite stable and good 😃16 t sitten·This could take years and days, but I'm still holding on to my 25,000 shares! Whether I lose 25,000 or 10,000 doesn't matter. I had faith in the company. But if things go wrong, the state covers almost 40% of the loss.
- 1 päivä sitten · Muokattu·MedWatch Latest Search Menu Drugs & Biotech Medtech & diagnostics Digital Health Regulation & Politics Discussion Career Clinical success could be historic – these biotech companies are nearing the finish line MedWatch has mapped the position of Norwegian biotech companies in the race to the market. Who could be the first company to give Norway a new drug – over ten years after Algeta's Xofigo success? BIOTECH LEADERS: These are leaders of Norwegian clinical-stage biotech: Michael Engsig (left), Nykode, Christian Kersten, Akigai, Øystein Rekdal, Lytix, Rizwan Hussain, Agiana, Øystein Soug, Oncoinvent, Thomas Bjarnsholt, Softox, Lars Prestegården, Cytovation, Per Walday, Exact, Arctic Bioscience, Christer Valderhaug, Erik Wiklund, Circio, Mark Gaffney, Calluna Pharma, Namir Hassan, Zelluna, Christian Lütken, Pharma Holding, Zeno Albisser, Hemispherian, Emanuele Ostuni, Artbio, Jethro Holter, Adjutec. | Photo: Marius Åmbakk Bjørkedal/Vidar Sandnes/Sebastian Brauer Hagel/Softox Solutions/Calluna Pharma/Hemispherian/Artbio/Arcticzymes BIOTICS LEADERS: These are the leaders of Norwegian biotech in clinical phase: Michael Engsig (left), Nykode, Christian Kersten, Akigai, Øystein Rekdal, Lytix, Rizwan Hussain, Agiana, Øystein Soug, Oncoinvent, Thomas Bjarnsholt, Softox, Lars Prestegården, Cytovation, Per Walday, Exact, Arctic Bioscience, Christer Valderhaug, Erik Wiklund, Circio, Mark Gaffney, Calluna Pharma, Namir Hassan, Zelluna, Christian Lütken, Pharma Holding, Zeno Albisser, Hemispherian, Emanuele Ostuni, Artbio, Jethro Holter, Adjutec. | Photo: Marius Åmbakk Bjørkedal/Vidar Sandnes/Sebastian Brauer Hagel/Softox Solutions/Calluna Pharma/Hemispherian/Artbio/Arcticzymes Sebastian Brauer Hagel Sebastian Brauer Hagel Already a subscriber? Log in here Get access to everything from MedWatch Personal subscription Annual payment Save 20% Full access for one person 6,880.00 NOK / year* Excl. VAT Price incl. VAT displayed at checkout Personal subscription Quarterly payment Full access for one person 2,150.00 NOK / quarter** Excl. VAT Price incl. VAT displayed at checkout Corporate subscription Multiple users Full access for multiple users Attractive price per user Try MedWatch for 14 days - and get access to all content. Get a non-binding trial subscription here. * Continues as an ongoing subscription and is billed annually. After 5 months of subscription, can be terminated with 1 month's notice until the end of a month. Minimum price is up to 4,013.33 NOK incl. VAT. equivalent to 7 months of subscription. Right of withdrawal according to the Consumer Contracts Act. Read more here. ** Continues as an ongoing subscription for 3 months at a time. Minimum price 2,150.00 NOK incl. VAT.. Can be terminated with 1 month's notice until the end of a 3-month period. Right of withdrawal according to the Consumer Purchases Act. Read more here. Share article Related articles MUST CHOOSE A PATH: A discovery made by oncologist Christian Kersten and colleagues over 15 years ago has grown into the drug candidate AKI-007. Now the company is faced with a choice: out-license internationally or build the company in Norway. | Photo: Marius Åmbakk Bjørkedal / Medwatch Behind what could be Norway's next drug on the market - must make crucial choices READY FOR CLINICAL STUDY: Margaret Yu, Medical Director of Artbio, is, together with the rest of the company, ready to enter the company's first phase 1 study. Artbio ready for phase 1 studies in the USA PRE-CLINICAL: Arctic Bioscience is approaching the pre-clinical phase for a new drug candidate, for the treatment of normal brain development in extremely premature children. | Photo: Marius Åmbakk Bjørkedal Refuses to give up after study failure Sign up for our newsletter Be ahead of the curve. Get information about the latest from the industry with our newsletter. Email address PITCHE WINNERS: From left: Nicolaj Højer Nielsen (Investor), Benedikte Stavik (winner), Mohammed Amarzguioui (Inven2), Morten Egeberg (SPARK). Joachim Paasche (Aleap/Veksthuset) also sat on the jury. Not pictured: Giacomo Roman. | Photo: Anne-Marie Korseberg Stokke. Research duo wins pitch competition with new hemorrhoid treatment These will forge biotech Norway with new accelerator program OUS researcher wins Nordic innovation competition CLEANING IN THE MANAGEMENT HIERARCHY: Maziar Mike Doustdar announced thousands of layoffs last week both in Denmark and internationally as part of the plan to turn around the crisis-stricken company. | Photo: Novo Nordisk Novo Nordisk clears job titles IMPROVEMENTS: Sanofi is demanding improvements in the British business environment if they are to continue investing in the country. However, the office pictured here is in France, at Vitry sur Seine. | Photo: AP Photo/Michel Euler/NTB Sanofi also freezes British investments DRUG BREXIT: MSD, Astra Zeneca and Eli Lilly are among the companies that are now reassessing investments in the UK. | Photo: Colourbox Pharmaceutical giants turn their backs on the UK – believe NHS policy scares away investments AMBITION: Ulrik Therkildsen and Human Bytes have an ambition to expand the agreement with South-Eastern Health to cover the entire country
- 1 päivä sitten · Muokattu·Circio has also not come up with a new date for the next quarterly report?????? Now it's win or lose for the company so we'll see which way it goes 😇
- 1 päivä sitten · Muokattu·Now Erik needs a real kick in the ass so he can give something back to his investors who have been long in this and believed in..........???? Time to cough up something concrete 🙉
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Oslo Børs
Määrä
Osto
50 000
Myynti
Määrä
4 000
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| - | - | - | - |
Ylin
-VWAP
Alin
-Vaihto ()
VWAP
Ylin
-Alin
-Vaihto ()
Välittäjätilasto
Dataa ei löytynyt